Belgium-based UCB has announced plans to invest $2 billion in the construction of a biologics manufacturing facility in the United States, marking the company’s first such plant in the country. The site will be located in Gwinnett County, near Atlanta, Georgia, close to the company’s U.S. headquarters in Smyrna.
The planned facility will span approximately 460,000 square feet and occupy a 79-acre site within the Rowen innovation district, a mixed-use development intended to attract corporate investment. The project is modeled after North Carolina’s Research Triangle Park and is situated near Emory University, Georgia Tech, and the University of Georgia.
Local officials approved UCB’s application on Tuesday, making the project the largest single corporate investment in Gwinnett County’s history. The site is located near Dacula, roughly 35 miles northeast of downtown Atlanta, and about a 45-minute drive from Smyrna. The development is also part of a larger 2,000-acre campus, where UCB will be the first global tenant.
The company expects the facility to generate a financial impact of approximately $5 billion. Once operational, the plant is projected to create around 330 permanent jobs, along with more than 1,000 construction roles during the development phase. Construction and design are anticipated to take between six and seven years.
UCB stated that the plant will manufacture biologics using advanced technologies, including artificial intelligence, robotics, and automation, producing around the clock. The company indicated that the site will serve as the central hub for its U.S. manufacturing operations and will support products such as the psoriasis treatment Bimzelx.
The investment follows an earlier announcement in June of last year, when UCB disclosed its intention to establish a large-scale manufacturing presence in the U.S. but had not yet identified a specific location. Prior to this decision, the company conducted a feasibility study and evaluated up to 15 potential sites across the country, focusing on regions with strong access to skilled talent.
“The real factors are about talent, location, quality of life, the innovation ecosystem,” said Taco van Tiel in an interview with Fierce.
UCB has largely relied on contract manufacturers to produce its drugs in the U.S. In addition to its headquarters in Smyrna, the company operates a research facility in the Boston area and conducts clinical research and development in North Carolina’s RTP region.
The company has reported a 26% increase in revenue to 7.74 billion euros ($8.7 billion) last year. Its workforce has grown by 68% since 2017, including a 121% increase in research and development roles. UCB employs nearly 2,000 people in the U.S. and more than 9,000 globally.
The Georgia project follows broader industry activity, as several biopharma companies have announced plans to expand manufacturing operations in the United States following policy initiatives aimed at increasing domestic production. UCB also plans to use the facility to help meet demand for products, including Bimzelx, which recorded significant sales growth in the U.S.
Why UCB Is Investing in Georgia
The decision by UCB to establish a large-scale manufacturing facility in Georgia is driven by the region’s strong life sciences ecosystem and skilled workforce. By choosing this location, UCB aims to enhance supply chain resilience and ensure faster delivery of critical therapies to patients.
The planned $2 billion biologics manufacturing facility in Georgia represents one of the largest recent investments in the U.S. life sciences sector. The project is expected to significantly enhance production capabilities for advanced therapies, particularly as demand for biologics continues to rise globally. With cutting-edge infrastructure and modern design, the facility will support large-scale manufacturing while maintaining strict regulatory and quality standards.
Advanced Technology and Innovation Focus
The new site will incorporate next-generation manufacturing technologies, including automation, digital monitoring systems, and data-driven process optimization. These capabilities are essential for ensuring consistent product quality and improving efficiency across complex biologics production processes. The facility is also expected to adopt sustainable practices, such as energy-efficient systems and waste reduction strategies, aligning with broader environmental goals in the pharmaceutical industry.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
